Videos
June 10, 2021
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
Videos
April 27, 2021
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Videos
April 21, 2021
William Bradley, MD, discusses 5-year follow-up results from the SOLO-1 trial, which aimed to assess the long-term efficacy and tolerability of maintenance olaparib for newly diagnosed advanced ovarian cancer.
Videos
April 21, 2021
Katherine Cain, PharmD, discusses results from a study comparing out-of-pocket costs between apixaban and enoxaparin for prevention of postoperative VTE in patients with gynecologic cancers.
Videos
March 30, 2021
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
Conference Coverage
March 30, 2021
A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the tolerability and dose modifications of PARP inhibitor therapies for ovarian cancer in the United States.
Conference Coverage
March 29, 2021
Study results support a lower starting dose of lenvatinib in clinical practice than what is currently recommended by the FDA.
Conference Coverage
March 22, 2021
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for commercially insured patients with advanced ovarian cancer, but not those covered under Medicare.
Conference Coverage
March 22, 2021
Minimally invasive surgery is cost-effective compared with laparotomy for suspicious ovarian masses, even though it is associated with increased risk of capsule rupture and death from ovarian cancer.